Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Non-Current Liabilities: 2022-2025

Historic Other Non-Current Liabilities for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $11.5 million.

  • Phathom Pharmaceuticals' Other Non-Current Liabilities rose 6.98% to $11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year increase of 6.98%. This contributed to the annual value of $11.5 million for FY2024, which is 18.56% up from last year.
  • According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Other Non-Current Liabilities is $11.5 million, which was down 0.00% from $11.5 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $11.5 million in Q4 2024 and a low of $7.5 million during Q1 2022.
  • In the last 3 years, Phathom Pharmaceuticals' Other Non-Current Liabilities had a median value of $10.4 million in 2024 and averaged $9.9 million.
  • Data for Phathom Pharmaceuticals' Other Non-Current Liabilities shows a peak YoY surged of 43.33% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Phathom Pharmaceuticals' Other Non-Current Liabilities stood at $7.5 million in 2022, then climbed by 29.33% to $9.7 million in 2023, then grew by 18.56% to $11.5 million in 2024, then grew by 6.98% to $11.5 million in 2025.
  • Its Other Non-Current Liabilities was $11.5 million in Q3 2025, compared to $11.5 million in Q2 2025 and $11.5 million in Q1 2025.